• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Part 3: Exploratory Protocols for Multimodal Foundation Model in Healthcare

Part 3: Exploratory Protocols for Multimodal Foundation Model in Healthcare

 

3.1 Wolfram Code – Example from Genomics, Volume 3 in Spanish Edition

Five comments of note are repeated here from the Original Book and from the New Genre, Genomics Volume 2, PART A & PART C because of their significance:

Genomics, Volume 3 in Spanish Edition

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B0BRD8JXTL $155

Comment #1: 

  • No other book covers the same topics in a single volume

Comment #2:

  • No other book incorporates 74 e-Proceedings created in real time by the Book’s authors and editors at conferences on Genomics

Comment #3:

  • No other book incorporates four collections of Tweets representing quotes from speakers at global leading conferences on Genomics

Comment #4:

  • No other book has 13 locations of Videos and Audio Podcasts that serve to enrich the e-Reader’s experience

Comment #5:

  • No other book has 326 articles on the topics covered and included in the title of this Book: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

The e-Reader is encouraged to read the Preface, the Introduction and the Epilogue to Genomics Volume 2

  • Original Volume Two:

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS and BioInformatics, Simulations and the Genome Ontology

On Amazon.com since 12/28/2019

https://www.amazon.com/dp/B08385KF87

AND

the e-Reader is encouraged to continue to Genomics Volume 1

Genomics Orientations for Personalized Medicine

VOLUME ONE

On Amazon.com since 23/11/2015

http://www.amazon.com/dp/B018DHBUO6

NEW GENRE Genomics, Volume Three:

Results of Medical Text Analysis with Natural Language Processing (NLP): Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS

https://www.amazon.com/dp/B0BRD8JXTL

Results of Medical Text Analysis with Natural Language Processing (NLP): Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, … de la investigación genómica Book 3) Kindle Edition

by Madison Davis (Author), Aviva Lev-Ari (Editor), Stephen J. Williams (Editor), Marcus W. Feldman (Editor) Format: Kindle Edition

Serie B: Fronteras de la investigación genómica 

(3 book series) Kindle Edition

by Larry H. Bernstein (Author) , Stephen J. Williams (Author) , Sudipta Saha (Author) , Ritu Saxena (Author) , Tilda Barliya (Author) , Anamika Sarkar (Author) , Marcus W. Feldman (Author) , Demet Sag (Author) , Prabodh kandala (Author) , Larry H. Bernstein (Author) , Aviva Lev-Ari (Author) , Madison Davis (Author)

https://www.amazon.com/dp/B0BQGZYZVT?binding=kindle_edition&ref=dbs_dp_rwt_sb_pc_tukn

Appendix to this volume – Wolfram Code

  • for Hypergraph Plots &
  • for Tree Diagram Plots 

NLP Code writing for 7/8 Parts 1,2,3,4,5,7,8

[No Code for Part 6 in Volume 3]

by

Madison Davis

Code used in production of Hyper-graph Plots at the Book Part Level

 

Hyper- 

graph Plot #1

 

for 1.1.1 based on

16 articles & on 14 keywords

wordSheet ={ 

protein,cancer,dna,gene,genes,rna,survival,immune,tumor,research,patients,human,

genome,expression

};

topN = Length[wordSheet];

words = {};

For[i = 1, i <= topN, i++,

words = Append[words, ToString[wordSheet[[i]]]]];

Print[words];

maxN = 3;

broadTerms = {};

words1 = {};

words2 = {};

For[i = 1, i <= topN, i++,If[Length[Position[WordData[], Extract[words, i]]] > 0,

broadTerms = Append[broadTerms, Flatten[Values[WordData[Extract[words, i], “BroaderTerms”]]]];

words1 = Append[words1, Extract[words, i]], words2 = Append[words2, Extract[words, i]]]];

For[i = 1, i <= Length[broadTerms], i++, If[Length[broadTerms[[i]]] > maxN, broadTerms[[i]] = broadTerms[[i]][[1 ;; maxN]]]];

 

edgeList = {};

edgeList = Append[edgeList,Prepend[words1, “”]] ;

For[i = 1, i <= Length[words1], i++,  edgeList = Append[edgeList, Append[broadTerms[[i]], words1[[i]]]]];

ResourceFunction[“HypergraphPlot”][edgeList, VertexSize -> 0.01, VertexLabels -> Automatic, PlotTheme -> “Detailed”, SubsetEdge -> False, SubsetBoundaryScale -> 7, VertexStyle ->

Red,”BaseLayout” -> “RadialEmbedding”,”SubsetEdgeStyle” -> ColorData[100, “ColorList”]]

Hypergraph Plot #2 

for 1.1.2

based on

17 articles

& on 12 keywords

wordSheet ={ 

cancer,mutations,patients,gene,disease,genetic,mutation,data,clinical,tumor,genes,

protein

};

topN = Length[wordSheet];

words = {};

For[i = 1, i <= topN, i++,

words = Append[words, ToString[wordSheet[[i]]]]];

Print[words];

Code used in production of Tree Diagram Plots

 

Tree Diagram Plot #1 

for 1.1.1 based on 16 articles & on 14 keywords

wordSheet ={ 

protein,cancer,dna,gene,genes,rna,survival,immune,tumor,research,patients,human,

genome,expression

};

topN = Length[wordSheet];

words = {};

For[i = 1, i <= topN, i++,

words = Append[words, ToString[wordSheet[[i]]]]];

Print[words];

maxN = 3;

broadTerms = {};

words1 = {};

words2 = {};

For[i = 1, i <= topN, i++,If[Length[Position[WordData[], Extract[words, i]]] > 0,

broadTerms = Append[broadTerms, Flatten[Values[WordData[Extract[words, i], “BroaderTerms”]]]];

words1 = Append[words1, Extract[words, i]], words2 = Append[words2, Extract[words, i]]]];

For[i = 1, i <= Length[broadTerms], i++, If[Length[broadTerms[[i]]] > maxN, broadTerms[[i]] = broadTerms[[i]][[1 ;; maxN]]]];

 

edgeList = {};

For[i = 1 , i <= Length[broadTerms], i++,  edgeList = Append[edgeList, broadTerms[[i]]]];

For[i = 1 , i <= Length[broadTerms], i++, For[j = 1, j <= Length[edgeList[[i]]], j++,  edgeList[[i]][[j]] = words1[[i]] -> edgeList[[i]][[j]]]];

For[i = 1 , i <= Length[words1], i++, edgeList = Append[edgeList, {“Chapter 1.1.1” -> words1[[i]]}]];

TreePlot[Flatten[edgeList], VertexSize -> 0.1, VertexLabels -> Automatic]

Tree Diagram Plot #2 

for 1.1.2

based on 17 articles & on 12 keywords

wordSheet ={ 

cancer,mutations,patients,gene,disease,genetic,mutation,data,clinical,tumor,genes,

protein

};

topN = Length[wordSheet];

words = {};

For[i = 1, i <= topN, i++,

words = Append[words, ToString[wordSheet[[i]]]]];

Print[words];

3.2 Pilot Study with UK-based TOP NLP company, 2021

 

3.3 Grok 4.1

  • Exploratory Protocol for Comparison of NLP to LLM on Same Oncology Slice

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD, KOL on Cancer & Oncology

https://pharmaceuticalintelligence.com/2025/12/08/exploratory-protocol-for-comparison-of-nlp-to-llm-on-same-oncology-slice/

  • 2025 Grok 4.1 Causal Reasoning & Multimodal on Identical Proprietary Oncology Corpus: From 673 to 5,312 Novel Biomedical Relationships: A Direct Head-to-Head Comparison with 2021 Static NLP – NEW Foundation Multimodal Model in Healthcare: LPBI Group’s Domain-aware Corpus Transforms Grok into the “Health Go-to Oracle”

Authors:

  • Stephen J. Williams, PhD (Chief Scientific Officer, LPBI Group)
  • Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief Journal and BioMed e-Series, LPBI Group)
  • Grok 4.1 by xAI

https://pharmaceuticalintelligence.com/2025/12/15/2025-grok-4-1-causal-reasoning-multimodal-on-identical-proprietary-oncology-corpus-from-673-to-5312-novel-biomedical-relationships-a-direct-head-to-head-comparison-with-2021-static-nlp-new-foun/

  • 2026 Grok Multimodal Causal Reasoning on Proprietary Cardiovascular Corpus: From 2021 Wolfram NLP Baseline to Thousands of Novel Relationships – A Second Head-to-Head Validation of LPBI’s Domain-Aware Training Advantage

    Authors:

    • Aviva Lev-Ari, PhD, RN (Founder & Editor-in-Chief, Journal and BioMed e-Series, LPBI Group)
    • Grok 4.1 by xAI

    https://pharmaceuticalintelligence.com/2026/01/06/2026-grok-multimodal-causal-reasoning-on-proprietary-cardiovascular-corpus-from-2021-wolfram-nlp-baseline-to-thousands-of-novel-relationships-a-second-head-to-head-validation-of-lpbi/

  • Authentic Relevance of LPBI Group’s Portfolio of IP as Proprietary Training Data Corpus for AI Initiatives at Big Pharma

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/2025/11/15/authentic-relevance-of-lpbi-groups-portfolio-of-ip-as-proprietary-training-data-corpus-for-ai-initiatives-at-big-pharma/

  • Generative AI Providers: Open Source and Closed source, @Google’s JAX AI stack versus @xAI @Grok

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2025/12/03/generative-ai-providers-open-source-and-closed-source-googles-jax-ai-stack-versus-xai-and-grok/

 

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,038 other subscribers
  • Recent Posts

    • Novartis and Bristol Myers Squibb halt CAR-T trial for autoimmune diseases over patient deaths: a potential issue with cell-based manufacturing September 15, 2026
    • FDA Contemplates Changes in Trial Design, Drug Development, and Use of AI in Clinical Trials September 15, 2026
    • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
    • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
    • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
    • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


%d